PARTNER WITH US IN RESEARCH

Click HERE to complete a questionnaire to be considered for future research opportunities

Studies Now Recruiting Participants

Please call 402-280-BONE(2663) or toll free at 1-800-368-5097 to inquire about our studies.

This project is aimed at recruiting 13-14 year old girls for a study looking at the role of dairy consumption on weight management.  Adolescence has been recognized as a key time in life in which young girls are at risk of becoming overweight. This is a study proposing that increasing the intake of dairy foods, which are easily accessible and nutrient-rich, will actually help reduce the risk of becoming overweight in these young girls.

Principal Investigator: Joan M. Lappe, PhD, RN, FAAN

Amount of time on study: Each child will be on study for 1 year.  We will be recruiting for this study over a 4 year period.

Your 13-14 year old daughter may qualify for a one year research study looking at the role of dairy intake on weight management. This study will attempt to show that increasing the intake of dairy foods, to the levels recommended by the American Academy of Pediatrics, will decrease the risk of overweight in these adolescent girls.

·        5 visits (one visit every 3 months)

·        Painless evaluations

·        Monetary Stipend will be given at each completed visit

Inclusion/Exclusion criteria:

• Healthy 13 and 14 year old girls
• No History of Milk Allergy or Lactose Intolerance
• No History of Chronic Diseases
• No Use of Medications including: steroids, weight reduction medications, oral contraceptives, Accutane/high dose Vitamin A, ADHD medications (except Straterra), seizure medications, or antidepressants.
• No Diagnosed eating disorders

Project manager: Margaret Begley, BA, BSN, RN
Contact Info:  MargaretBegley@creighton.edu  or 402-280-4578

This is a study on women between the ages of 50-55, who have good bone density and those that may also have experienced some bone loss.

Principal Investigator: Robert R. Recker, MD, MACP, FACE.

This is a genetic study where we are looking for women in a strict age group who meet certain density standards.  Those who meet these criteria will be asked to donate blood and other samples to look at their individual genetic make up.

Amount of Time on Study:  This study can be done in 3 visits to our office, the visits can be right after each but they do all need to be on different days due to lab restrictions.

Inclusion/Exclusion criteria:

Caucasian Women age 50-55

Subjects can not be on hormones of any kind (Exp: Estrogen, Premarin®, birth control pills)

No osteoporosis medication (Exp: Fosamax®, Boniva®, Actonel®, Forteo®, Evista®)

No cholesterol medications (Exp: Lipitor)

No steroid medications in the last 6 months (Exp: Prednisone, Cortisone)

No seizure medications in the last 6 months (Exp: Dilantin, Phenobarbital)

In relatively good health

Project Manager: Jennifer A. Larsen, R. T. (R) (BD) (ARRT), CDT
Contact Info:   JenniferLarsen@creighton.edu or 402-280-4489

Diabetes is very common and has many complications, including cardiovascular, renal and nervous system effects. An increased skeletal fracture risk in diabetes has only recently been recognized.

Principal Investigator: Laura A. G. Armas, MD

Bone is constantly repairing itself and this study is designed to use various methods to determine if diabetes affects the repair process.

Amount of time on study: The study requires 3 visits to our Center over a 2-3 month time period.

Inclusion/Exclusion criteria:

• Men and women, age 19-50
• You must be a Type 1 diabetic for at least 3 years
• Must be taking insulin
• No history of cancer (skin cancer is ok)
• No oral steroid medications, seizure medications, osteoporosis medications, metformin, Actos/Avandia or diuretics
• No unstable angina, heart attack, or uncontrolled high blood pressure

 Project Manager: Julie Stubby, RN, BSN
Contact Info: JulieStubby@creighton.edu or 402-280-4958

The purpose of this study is to compare the effects of two FDA-approved medications on osteoporosis.

Principal Investigator: Robert R. Recker, MD, MACP, FACE.

Length of study: 12-14 months.

This study will compare two osteoporosis medications to observe how they improve bone health.

Inclusion/Exclusion criteria:

• Female, age 55-89, postmenopausal for at least 2 years (i.e. at least 2 years since last menstrual period).
• No history of taking IV or injectable osteoporosis medications
• Not currently on hormones, Evista®, steroids or seizure medications

Project Manager: Julie Stubby, RN, BSN
Contact Info: JulieStubby@creighton.edu or 402-280-4958

Please call 402-280-BONE(2663) or toll free at 1-800-368-5097 to inquire about our studies.

To investigate underlying causes of osteoporosis in postmenopausal women.

Principal Investigator: Robert R. Recker, MD, MACP, FACE.

Length of study:  4 to 6 months.

This is a study to learn more about bone quality and causes of fracture.

Inclusion/Exclusion criteria:

• Female 45-70 years of age, at least 4 years past menopause, no osteoporosis treatment, steroids, or hormones in the last 6 months.
   

• A broken bone in the last 5 years that was not a result of a car accident.

Project manager: Chris Von Buettner, RN, BSN

Contact Info: ChristineVonBuettner@creighton.edu or 402-280-4611

This study is looking at the effect smoking has on bone health.

Principal Investigator: Peng Xiao, PhD

This study is looking at how smoking effects bone health and the difference between smokers and non-smokers bones.

Amount of time on study: 1 visit

Inclusion/Exclusion criteria:

• Be Caucasian
• Be age 30-40 and pre-menopausal
• Not have taken hormones in the last year (including birth control medications)
• Not have taken osteoporosis medication in the last year
• Not currently on any cholesterol medication
• Not have taken steroid medication in the last 6 months
• Not have taken seizure medications in the last 6 months
• Currently in good health

Project Manager: Jennifer A. Larsen, R. T. (R) (BD) (ARRT), CDT
Contact Info:  JenniferLarsen@creighton.edu or 402-280-4489
 

  This study focuses upon premenopausal women.  This study will fully evaluate women with idiopathic osteoporosis (IOP), as well as women with healthy bone density to serve as controls.

Principal Investigator: Robert R. Recker, MD, MACP, FACE.

Osteoporosis is most commonly diagnosed in postmenopausal women but this study focuses upon premenopausal women.  A group in whom osteoporosis occurs not uncommonly but about which our knowledge is woefully inadequate. Although many young women with osteoporosis have an underlying cause  (e.g., cystic fibrosis, anorexia nervosa, glucocorticoid exposure), other young women with osteoporosis do not have a definable cause or clear-cut risk factors. They can be said to have idiopathic osteoporosis (IOP).  This study will fully evaluate women with IOP as well as women with healthy bone density to serve as controls.

Amount of time on study: 6 to 8 months

Inclusion/Exclusion criteria:

Age 20-48 Pre-menopausal women

Looking for either women with osteoporosis diagnosed on our DXA machine or women who have experienced low-trauma fractures after the age 18.

• no use of oral contraceptives, depot progesterone, estrogen preparations, raloxifene, or calcitonin within the last 3 months no use of bisphosphonates within the last 12 months or total exposure to bisphosphonates greater than 1 year
• no use of PTH, glucocorticoids, anticonvulsants, anticoagulants, diuretics, or methotrexate use ever
• no use of zolendronate within the past 2 years

Project Manager: Jeanette LeMaster, RN, CCRC
Contact: Info:  JeanetteLeMaster@creighton.edu or 402-280-4839

The purpose of this study is to find out if giving an injection of a new product in the hip bone can make the hip stronger and less likely to break later on.

Principal Investigator: Robert R. Recker, MD, MACP, FACE.

Length of study:  3 years (10 visits total)

Some of the persons on this study will receive one injection in one of their hip bones. All women on the study will be receiving Fosamax®, calcium and Vitamin D supplements while on study. 

You may be able to participate in this study if you:

• Are at least 65 years old and post-menopausal
• Have either never received osteoporosis treatment or have taken a bisphosphonate (such as Actonel®, Fosamax®, or Boniva®) for the past 1-5 years
• Have not been on any hormones or Evista® in the past 12 months

Project Manager: Jennifer A. Larsen, R. T. (R) (BD) (ARRT), CDT
Contact Info:  JenniferLarsen@creighton.edu or 402-280-4489